Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Valganciclovir (Valcyte®) tablets are recommended as an option for use within NHS Wales for 200 days prophylaxis of cytomegalovirus (CMV) disease in CMV-negative kidney transplant patients who have received a transplant from a CMV-positive donor. AWMSG is of the opinion that valganciclovir (Valcyte®) tablets are not suitable for shared care within NHS Wales for the above indication. |
|||
|
|||
Medicine details |
|||
| Medicine name | valganciclovir (Valcyte®) | ||
| Formulation | 450 mg film-coated tablet | ||
| Reference number | 812 | ||
| Indication | Licence extension for 200 days prophylaxis of cytomegalovirus (CMV) disease in CMV-negative kidney transplant patients who have received a transplant from a CMV-positive donor |
||
| Company | Roche Products Ltd | ||
| BNF chapter | Infections | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 0611 | ||
| NMG meeting date | 11/05/2011 | ||
| AWMSG meeting date | 15/06/2011 | ||
| Ratification by Welsh Government | 01/09/2011 | ||
| Date of issue | 07/09/2011 | ||